Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1989-04-13
1991-07-16
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3700
Patent
active
050325752
ABSTRACT:
Method using a non-steroidal antiinflammatory compound, such as indomethacin and/or a growth factor that causes a change in cell function when bound to a specific cell surface receptor, such as epidermal growth factor (EGF), to enhance healing and restore function of the corneal endothelium. The compositions can be administered alone, in combination, or in sequence, before or after injury, for example, in an irrigation solution or in combination with a nutritive solution for storage of a cornea prior to transplant.
Examples of useful growth factors include, in addition to EGF and EGF-like compounds, fragments of EGF containing the receptor binding region, and EGF modified to improve stability, increase half-life, or enhance permeation into the eye. Examples of other non-steroidal antiinflammatories include aspirin, ibuprofen, and suprofen. The composition can be applied topically to the eye or delivered in a controlled fashion by means of a material such as a polymeric implant, gel, or liposomes.
The effective dosage is that amount which promotes closure of corneal endothelial tissue and restores function, i.e., restores permeability, including both barrier function and pumping function.
REFERENCES:
patent: 4559343 (1985-12-01), Han et al.
patent: 4604234 (1986-08-01), Fujii et al.
Neufeld et al., Invest. Ophthal. Vis. Sci., 26(10) 1437-1442 (1986).
Jumblatt et al. Invest. Opthal. Vis. Sci., 29(4): 586-593 (Apr. 1988).
Burstein, N. L., J. Ocular Pharm. 3(3) 263-277 (1987).
Singh et al., Amer. J. Ophthal. 103(6) 802-807 (1987).
Van Brunt and Klausner, Biotechnology 6(1), 25-30 (Jan. 1988).
Chiron Ophthalmics, "Epidermal Growth Factor", Product Brochure (date unknown, no earlier than 1987-1988).
Tsutsumi, et al., J. Clin. Invest. 81(4), 1067-1071 (Apr. 1988).
Singh and Foster, Amer. J. Ophthal. 103(6), 802-807 (1987).
Petroutsos, et al., Ophthalmic Res. 18, 299-300 (1986).
Watanabe, Iu Igakuzassi 36(1), 1-8 (1984), Chem. Abstr. 103:207534t, 1985.
Watanabe, et al., Atarashii Ganka 1(5), 681-684 (1984) (Chem. Abstr. 102:126333d 1985).
Woost et al., Exp. Eye Res. 40, 47-60 (1985).
Neufeld et al., Invest. Ophthal. Vis. Sci., (26)10:1437-1442 (1986).
Raymond et al., Invest. Ophthal. Vis. Sci. (27)4:474-479 (1986).
Joyce Nancy C.
Jumblatt Marcia M.
Neufeld Arthur H.
Eye Research Institute of Retina Foundation, Inc.
Fay Zohreh A.
Friedman Stanley J.
LandOfFree
Method for enhancing healing of corneal endothelial wounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for enhancing healing of corneal endothelial wounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for enhancing healing of corneal endothelial wounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-131838